TP53 and acute lymphoblastic leukemia: Small-molecule MDM2 antagonists, which target the p53-MDM2 interaction leading to p53-mediated apoptosis, may synergize with current TKIs-based therapies in Ph+ ALL patients with wild-type p53 and may represent a valuable strategy for TKIs resistant patients.